Therapy for the treatment of disease

Abstract

Disclosed herein are pharmaceutical compositions comprising various combinations of an antimuscarinic or an anticholinergic agent, a compound that causes stimulation of salivary glands, and a compound that relieves constipation. Also disclosed are methods of treating a patient suffering from overactive bladder comprising administering to the patient the above pharmaceutical composition.

1 . A method of improving quality of sleep in a patient suffering from overactive bladder, the method comprising
 identifying a patient in need thereof, and   administering to the patient a therapeutically effective amount of oxybutynin or tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, and pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof,   whereby the quality of sleep in the patient is improved.   
   
   
       2 . The method of  claim 1 , comprising administering oxybutynin, a free base thereof, or a pharmaceutically acceptable salt thereof. 
   
   
       3 . The method of  claim 1 , comprising administering tolterodine, a free base thereof, or a pharmaceutically acceptable salt thereof. 
   
   
       4 . The method of  claim 1 , wherein the oxybutynin or tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, and the pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof, are administered more or less simultaneously. 
   
   
       5 . The method of  claim 1 , wherein the oxybutynin or tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, is administered prior to the pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof. 
   
   
       6 . The method of  claim 1 , wherein the oxybutynin or tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, is administered subsequent to the pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof. 
   
   
       7 . The method of  claim 1 , wherein the oxybutynin or tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, and the pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof, are together disposed in the same dosage form. 
   
   
       8 . The method of  claim 1 , wherein the oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, is administered at a dose of between 0.5 mg to 2 mg. 
   
   
       9 . The method of  claim 1 , wherein the tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, is administered at a dose of between 0.05 mg to 50 mg. 
   
   
       10 . The method of  claim 1 , wherein the pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof, is administered at a dose of between 0.05 mg to 50 mg. 
   
   
       11 . A method of improving quality of sleep in a patient suffering from overactive bladder, the method comprising
 identifying a patient in need thereof, and   administering to the patient oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, at a dose of between 0.5 mg to 2 mg and pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof at a dose of between 0.05 mg to 50 mg,   whereby the quality of sleep in the patient is improved.   
   
   
       12 . The method of  claim 11 , wherein the oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, and the pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof, are administered more or less simultaneously. 
   
   
       13 . The method of  claim 11 , wherein the oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, is administered prior to the pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof. 
   
   
       14 . The method of  claim 11 , wherein the oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, is administered subsequent to the pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof. 
   
   
       15 . The method of  claim 11 , wherein the oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, and the pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof, are together disposed in the same dosage form. 
   
   
       16 . A method of improving quality of sleep in a patient suffering from overactive bladder, the method comprising
 identifying a patient in need thereof, and   administering to the patient tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, at a dose of between 0.05 mg to 50 mg and pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof at a dose of between 0.05 mg to 50 mg,   whereby the quality of sleep in the patient is improved.   
   
   
       17 . The method of  claim 16 , wherein the oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, and the pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof, are administered more or less simultaneously. 
   
   
       18 . The method of  claim 16 , wherein the tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, is administered prior to the pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof. 
   
   
       19 . The method of  claim 16 , wherein the tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, is administered subsequent to the pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof. 
   
   
       20 . The method of  claim 16 , wherein the tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, and the pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof, are together disposed in the same dosage form.